

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Yestar Healthcare Holdings Company Limited**

**巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

- (1) CHANGE OF EXECUTIVE DIRECTOR;**
- (2) CHANGE OF CHIEF FINANCIAL OFFICER;**
- (3) CHANGE OF AUTHORIZED REPRESENTATIVE;**
- AND**
- (4) CHANGE IN COMPOSITION OF BOARD COMMITTEE**

### **RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF FINANCIAL OFFICER, AUTHORIZED REPRESENTATIVE AND MEMBER OF INVESTMENT COMMITTEE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Yestar Healthcare Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that with effect from 15 October 2024, Ms. Wang Hong (“**Ms. Wang**”) has tendered her resignation as an executive Director of the Company, the chief financial officer of the Company (the “**Chief Financial Officer**”), an authorized representative of the Company (“**Authorized Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”), and a member of the investment committee of the Board (the “**Investment Committee**”) in order to devote more time to her family. Ms. Wang will continue to work for the Group with a new role as a senior advisor of the Group.

Ms. Wang has confirmed to the Company that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Wang for her valuable contribution to the Group during her tenure of service as an executive Director, the Chief Financial Director, an Authorized Representative and a member of the Investment Committee.

## APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that, Mr. Qiao Jinrong (喬金榮) (“**Mr. Qiao**”) has been appointed as an executive Director of the Company with effect from 15 October 2024. The biographical details of Mr. Qiao are set out below:

Mr. Qiao, aged 43, graduated from Nanhua University\* (南華大學) with a bachelor’s degree in accounting. He has over 20 years of experience in accounting and financial management. From 2004 to 2007, Mr. Qiao handled cost accounting at Shanghai Yanghang Tongcai Limited\* (上海楊行銅材有限公司). From 2007 to 2008, Mr. Qiao handled cost accounting at Johnson Healthcare Technology (Shanghai) Company Limited\* (喬山健康科技(上海)有限公司). From 2008 to 2013, Mr. Qiao held the position of finance supervisor at Yihai Jiali Jinlong Yuliangyou Food Shares Limited\* (益海嘉里金龍魚糧油食品股份有限公司). From 2013 to 2022, Mr. Qiao held the position of regional chief financial officer at the Company. From March 2022 to October 2022, Mr. Qiao held the position as the chief financial officer at the Shanghai Medical Equipment Company Limited\* (上海醫療器械股份有限公司). From May 2023 to May 2024, Mr. Qiao held the position of chief financial officer at Jingwei Shida Medial Technology (Suzhou) Limited\* (精微視達醫療科技(蘇州)有限公司). Since July 2024, Mr. Qiao has been the chief financial officer of subsidiaries of the Company. Mr. Qiao possesses extensive experience in several aspects such as financial management and corporate governance which would allow him to leverage such to benefit the operation and development of the Group.

Mr. Qiao will enter into a service agreement and a letter of appointment with the Company respectively for an initial term of 3 years commencing with effect from 15 October 2024. Mr. Qiao shall hold office until the next annual general meeting of the Company after his appointment and shall be subject to retirement and re-election at such meeting in accordance with the articles of association of the Company. The Board and the remuneration committee of the Company (“**Remuneration Committee**”) have determined Mr. Qiao an emolument of RMB646,800 per annum with reference to his contribution, experience, duties and responsibilities, the Company’s remuneration policy, the prevailing market conditions and recommendations of the Remuneration Committee. The remuneration package will be subject to annual review by the Remuneration Committee and the Board from time to time with reference to his responsibility and performance.

As at the date of this announcement, save as disclosed above, Mr. Qiao (i) does not hold any other directorship in other public company the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not have any relationship with any other directors, senior management or substantial or controlling shareholders (having the meaning ascribed to them under Listing Rules of the Company; (iii) does not hold any position of the Company and other companies within the Group; and (iv) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter that needs to be brought to the attention of holders of securities of the Company in relation to the aforesaid appointment of Mr. Qiao.

The Board would like to express its warmest welcome to Mr. Qiao on his appointment.

**APPOINTMENT OF CHIEF FINANCIAL OFFICER, AUTHORIZED REPRESENTATIVE AND MEMBER OF INVESTMENT COMMITTEE**

The Board hereby further announces that with effect from 15 October 2024, Mr. Qiao, an executive Director, has been appointed as the Chief Financial Officer, a member of the Investment Committee and an Authorized Representative of the Company.

By order of the Board  
**Yestar Healthcare Holdings Company Limited**  
**Liao Changxiang**  
*Executive Director and Chief Executive Officer*

Hong Kong, 15 October 2024

*As at the date of this announcement, the executive Directors are Ms. Liao Changxiang and Mr. Qiao Jinrong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Mr. Koeswondo Michael David.*

\* *for identification purpose only*